Encouraged by positive preclinical data with Tumorad, Spago Nanomedical has intensified preparations for the upcoming phase I/IIa study in cancer patients.
The company also reported advancements with the contrast agent SpagoPix. BioStock reached out to CEO Mats Hansen for a comment on the Q1 report.
First North-listed Spago Nanomedical’s projects are based on a technology.